The animal health company is expanding its pipeline across obesity, cancer, chronic kidney disease, cardiology, anxiety, and other areas of unmet need
Parsippany, New Jersey, 10 August 2026 – Zoetis is strengthening its focus on next-generation animal healthcare as it advances a broad pipeline of potential treatments for pets facing chronic and complex health conditions. The company says its pipeline includes more than 12 potential blockbuster candidates across areas such as chronic kidney disease, oncology, cardiology, anxiety, and obesity.
The company defines potential blockbuster products as treatments with expected future annual sales potential of at least $100 million. Its research pipeline is designed to address significant unmet needs in veterinary medicine while expanding treatment options for companion animals.
Pet healthcare is becoming increasingly sophisticated as owners and veterinarians seek better ways to manage conditions that can affect animals over many years. Zoetis is responding by investing in new therapies, diagnostics, and treatment approaches that could improve disease management and quality of life for pets.
One of the major areas of focus is chronic kidney disease. The company is developing potential new treatments for this condition as part of its efforts to expand care for pets with long-term illnesses. Chronic diseases can require ongoing management, creating demand for therapies that are easier to administer and can provide better outcomes.
Cancer is another important area in the company’s research program. Zoetis says cancer affects approximately one in four dogs during their lifetime, with the risk increasing among older animals. Its oncology research includes approaches involving monoclonal antibodies, therapies designed to slow tumor growth, cancer vaccines, and diagnostic tools that could support earlier detection and more targeted treatment.
The company is also exploring new treatments for heart conditions in dogs and cats. Its research focuses on conditions such as mitral valve disease in dogs and hypertrophic cardiomyopathy in cats, to develop therapies that can help detect disease earlier and slow its progression.
Pet anxiety and obesity are also emerging areas of interest. Zoetis is exploring potential therapies for anxiety that could offer faster action and fewer limitations than some existing approaches. Its longer-term research also includes metabolic diseases such as diabetes and obesity, reflecting growing attention to the health challenges associated with excess weight in pets.
The company’s research efforts build on a large investment in animal health innovation. Zoetis reports that it has invested more than $6 billion in research and development since 2013. As of the end of 2025, its portfolio included 18 products that generated at least $100 million in annual revenue, while its research activities covered 15 therapeutic areas and approximately 90 therapeutic targets.
Zoetis is also continuing to expand existing treatments through new formulations, additional uses, and geographic approvals. Recent developments include approvals for Lenivia and Portela, monoclonal antibody therapies designed to manage osteoarthritis pain in dogs and cats, respectively. The company expects these products to expand access to longer-acting pain management options in additional markets.
The growing pipeline comes as the broader animal health industry continues to develop. Zoetis estimates that the global animal health market could approach $90 billion by 2035, driven by rising pet ownership, higher expectations for veterinary care, and increasing demand for effective treatments for chronic conditions.
For Zoetis, the focus is not limited to developing individual medicines. The company is combining therapeutics with diagnostics, vaccines, digital tools, and other technologies as it works toward a broader approach to animal healthcare. Its research strategy also includes using data and artificial intelligence to support drug discovery and improve target identification.
As veterinary medicine continues to advance, conditions once considered difficult to manage are becoming important areas for innovation. Zoetis’s expanding pipeline reflects this shift, with research aimed at helping pets live longer and healthier lives while giving veterinarians more tools to prevent, detect, and treat disease.
With more than 12 potential blockbuster candidates in development, the company’s next phase of growth will depend on research progress, regulatory approvals, and the successful introduction of new therapies. For pet owners and veterinarians, these developments could eventually translate into more treatment choices for some of the most challenging conditions affecting companion animals.